GLP-1 Studio Podcast – Studio Special

Host: Amanda Bonello

On November 6th, 2025, the White House announced pricing agreements with Eli Lilly and Novo Nordisk that could reshape GLP-1 access for millions of Americans.

For the first time ever, Medicare and Medicaid will cover GLP-1 medications for obesity—with just a $50 copay. Brand name medications like Ozempic, Wegovy, and Zepbound are coming down to Most-Favored-Nation pricing, finally putting Americans on par with what other countries pay.

Discounted cash pay prices through TrumpRx are expected by the end of 2025. The full Medicare and Medicaid rollout is expected by April 2026.

For those who've been rationing doses, going without, or watching every door close—there is finally hope.

In this episode:

What the TrumpRx program means for pricing

How Most-Favored-Nation pricing works

What changes for Medicare, Medicaid, and commercial insurance

What this moment means after a year of advocacy

Resources:

Full pricing breakdown chart in the article below

Data sources: White House Fact Sheet (11/6/25), Eli Lilly & Co. press release (11/6/25), Novo Nordisk company announcement No. 32/2025

Connect with Amanda Bonello and the GLP-1 Studio Podcast: Learn more at GLP1Studio.com

Disclaimer: This content is for informational and advocacy purposes only. It reflects my personal understanding of recent policy announcements and publicly available information. I am not a medical professional or government representative. Always consult your healthcare provider for medical advice and check official sources for current policy and coverage details.

Get full access to GLP-1 Studio at glp1studio.substack.com/subscribe